The expansion is part of Governor DeSantis' allocation of additional doses of the Moderna vaccine to be administered to individuals ages 65 and older.
Eligible individuals can make appointments using the online reservation system at publix.com/covidvaccine, with vaccinations starting Thursday, Jan. 14.
The announcement brings the total number of Publix pharmacies offering COVID-19 vaccinations to 105 in 12 counties.
Vaccinations are provided to eligible individuals, by appointment only, while supplies last, and at no cost to the individual. Customers with health insurance will need to bring their insurance card to their scheduled appointment.
Customers without health insurance will need to provide their driver's license or Social Security number.
This expansion comes after the company received and distributed its first shipment of vaccines.
Publix continues to communicate with the state of Florida and the other six states in its operating area to provide COVID-19 vaccinations as part of their distribution efforts.
Publix, the largest employee-owned company in the US with more than 225,000 associates, currently operates 1,264 stores in Florida, Georgia, Alabama, Tennessee, South Carolina, North Carolina and Virginia.
Pfizer and BioNTech granted FDA approval for XFG-adapted COVID-19 vaccine
4basebio announces strategic collaboration with Genezen
Charles River and Medigen collaborate on next-generation enterovirus vaccine development
Innorna Nominated for 2026 Prix Galien USA Best Startup Award
Sanofi's MenQuadfi receives EU approval for infants from six weeks
Evaxion to present three-year cancer vaccine data at ESMO Congress 2026
Evaxion presents new preclinical data on cytomegalovirus vaccine EVX-V1
Northwest Biotherapeutics presents on propensity score matching at BNOS 2026
Taiwan biomedical startups hold over 100 business meetings at BIO 2026
SK bioscience to lead Gates Foundation-funded ROTOR project
Anixa Biosciences' breast cancer vaccine technology granted first Korean patent
Transgene expands myvac platform into non-small cell lung cancer with TG4070
Replicate Bioscience awarded Gates Foundation grant to advance srRNA vaccine candidates for TB